Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$3.14 USD
-0.08 (-2.48%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $3.17 +0.03 (0.96%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NERV 3.14 -0.08(-2.48%)
Will NERV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NERV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NERV
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
NERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Other News for NERV
Minerva Neurosciences Announces Board and Audit Committee Changes
Minerva price target lowered by $4 at H.C. Wainwright, here's why
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024
Minerva Neurosciences: Q1 Earnings Snapshot
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates